期刊文献+

某市三级甲等精神病专科医院2017年多种抗精神病药物联合使用分析 被引量:1

Combined Utilization of a Variety of Antipsychotics in Tertiary A Psychiatric Hospital in a City
下载PDF
导出
摘要 目的分析驻马店市第二人民医院2017年多种抗精神病药物联合使用情况,为多种抗精神病药物的联合使用提供更多的经验和支持。方法通过电子病历查阅2017年出院时≥3种抗精神病药物联合使用的59例患者的病历相关信息。结果驻马店市第二人民医院多种抗精神病药物的联合使用率0.63%;联合使用多种抗精神病药物的患者均诊断精神分裂症,其中未分化型和偏执型分别占72.9%、30.5%;非典型抗精神病药物在驻马店市第二人民医院临床联合用药中占主导地位(占91.7%)。结论驻马店市第二人民医院多种抗精神病药物的联合使用基本合理,联合使用抗精神病药物要有明确的指征和评估标准,确保患者安全。 Objective To analyze the combination of multiple antipsychotic drugs in the hospital in 2017 and provide more experience and support for the combined utilization of multiple antipsychotic drugs. Methods The medical history information of 59 patients with ≥3 kinds of antipsychotics used at hospital discharge in 2017 was accessed through electronic medical record. Results The combined utilization rate of multiple antipsychotic drugs in the hospital was 0.63%. Patients who had combined utilization of a variety of antipsychotics were diagnosed as schizophrenia. Undifferentiated and paranoid schizophrenic patients accounted for 72.9% and 30.5% of patients with multiple antipsychotics. In Zhuamadian No. 2 People’s Hospital, antipsychotics has played dominated role(accounting for 91.7%). Conclusion The combined use of multiple antipsychotics in the hospital is basically reasonable. Combination use of antipsychotic drugs have a clear indication and evaluation criteria to ensure patient safety.
作者 樊凌姿 FAN Ling-zi(Zhumadian No.2 People’s Hospital,Zhumadian,Henan,463000,China)
出处 《黑龙江医学》 2020年第2期249-251,共3页 Heilongjiang Medical Journal
关键词 多种抗精神病药物 联合使用 分析 A variety of antipsychotics Combined utilization Analysis
  • 相关文献

参考文献4

二级参考文献65

  • 1司天梅,舒良,于欣,马崔,王高华,白培深,刘协和,纪丽萍,师建国,陈宪生,梅其一,栗克清,张鸿燕,马弘.10省市抗精神病药使用现况的调查[J].中华精神科杂志,2004,37(3):152-155. 被引量:95
  • 2陈俊,王红星,徐鹤定,闻晖,方贻儒,王祖承.住院精神疾病患者药物治疗现况时点调查[J].药物流行病学杂志,2005,14(2):83-85. 被引量:23
  • 3世界卫生组织 范肖冬 汪向东 于欣 译.ICD-10精神与行为障碍分类临床描述与诊断要点[M].北京:人民卫生出版社,1993.70-106.
  • 4舒良.精神分裂症防治指南[M].北京:北京大学医学出版社,2007:64.
  • 5Kane JM, Correll CU. Past and present progress in the pharmaco- logic treatment of schizophrenia [J]. J Clin Psychiatry, 2010, 71 (9): 1115 - 1124.
  • 6Leucht S, Heres S, Kisslirig W, et al. Evidence-based pharmacother- apy of schizophrenia [J]. Int J Neuropsychopharmacol, 2011, 14 (2) : 269 -284.
  • 7Crossley NA, Constante M, Mcguire P, et al. Efficacy of atypical v. typical antlpsychotics in the treatment of early psychosis: recta-a- nalysis [J]. Br J Psychiatry, 2010, 196(6):434 -439.
  • 8Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition [ J]. Am J Psychiatry., 2004, 161( Suppl 2): 1 -56.
  • 9Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizo- phrenia and related disorders [ J]. Aust N Z J Psychiatry, 2005, 39 (1 -2):1 -30.
  • 10Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia-changes and challenges [J]. Int Rev Psychiatry, 2008, 20(5) : 460 -468.

共引文献67

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部